Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 12 - 21 tags : Treatment save search
Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA
Published: 2021-12-21 (Crawled : 20:20) - jaguarhealth.gcs-web.com
JAGX | $0.1657 -6.44% 21M
|
Health Technology
|
| O: -7.25%
H: 3.91%
C: -7.81%
treatment fda health approval diarrhea therapy crofelemer
Global Industrial Wastewater Treatment Chemicals Market (2021 to 2026) - Increase in the Demand for Specific Formulations Presents Opportunities
Published: 2021-12-21 (Crawled : 23:00) - prnewswire.com
PNR 4 | $78.86 0.48% 160K
|
Producer Manufacturing
|
| O: 0.28%
H: 0.51%
C: -0.61%
ECL | $218.43 -0.36% 240K
|
Process Industries
|
| O: -0.19%
H: 1.04%
C: 0.79%
IOSP | $122.125 1.08% 12K
|
Process Industries
|
| O: -0.23%
H: 0.64%
C: 0.24%
treatment ema als trial
Varicose Vein Treatment Market to reach US$ 1,059.9 Mn by end of 2028, Says Coherent Market Insights
Published: 2021-12-21 (Crawled : 19:00) - prnewswire.com
ANGO | $6.155 0.57% 160K
|
Health Technology
|
| O: 0.08%
H: 3.94%
C: 3.64%
treatment
Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Published: 2021-12-21 (Crawled : 15:00) - biospace.com/
DCPH | $14.3 0.49% 67K
|
Health Technology
|
| O: 0.1%
H: 6.41%
C: 4.98%
qinlock treatment gastrointestinal approval test
Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia
Published: 2021-12-21 (Crawled : 14:30) - biospace.com/
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: 0.2%
H: 0.74%
C: 0.33%
RIGL | $1.055 0.48% 260K
|
Health Technology
|
| O: 2.25%
H: 0.37%
C: -0.73%
treatment trial chronic immune phase 3
Systemic Mastocytosis Treatments Gain Hope Due To Increasing Novel Treatment Options
Published: 2021-12-21 (Crawled : 14:00) - prnewswire.com
LGVN | News P 0 d | $1.99 -1.0% 250K
|
|
| O: 10.04%
H: 10.86%
C: 1.7%
TAK | News | $13.185 0.19% 430K
|
Health Technology
|
| O: -0.29%
H: 0.14%
C: 0.07%
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: 0.45%
H: 0.39%
C: -0.89%
HOTH | $1.18 740
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: -2.64%
AMGN | $266.895 1.58% 950K
|
Health Technology
|
| O: 0.25%
H: 1.22%
C: 0.17%
treatment
LianBio Announces Infigratinib Approved Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China
Published: 2021-12-21 (Crawled : 13:30) - biospace.com/
LIAN | $4.92 0.41% 0.41% 410K
|
Professional, Scientific, and T...
|
| O: 6.24%
H: 0.13%
C: -6.63%
BBIO | $24.55 -1.6% 790K
|
Health Technology
|
| O: 0.07%
H: 4.03%
C: 2.15%
treatment china
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer
Published: 2021-12-21 (Crawled : 13:00) - hepionpharma.com
HEPA | $2.1118 13K
|
Health Technology
|
| O: 0.83%
H: 7.38%
C: 0.82%
crv431 treatment fda als clearance application liver fda clearance cancer
Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Published: 2021-12-21 (Crawled : 13:00) - biospace.com/
CLSD | $1.42 7.58% 130K
|
Health Technology
|
| O: -1.03%
H: 4.18%
C: 0.7%
treatment axitinib trial cls-ax phase 1 positive results
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors
Published: 2021-12-21 (Crawled : 13:00) - biospace.com/
RPTX 4 | $3.09 2.32% 77K
|
Health Technology
|
| O: 2.22%
H: 3.86%
C: 2.64%
rp-6306 treatment solid tumors trial therapeutics phase 1 gemcitabine
European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
Published: 2021-12-21 (Crawled : 11:00) - biospace.com/
GILD | News | $66.33 0.26% 2.8M
|
Health Technology
|
| O: 0.0%
H: 0.17%
C: -0.87%
covid-19 treatment europe risk oxygen covid disease
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.054 50.0% 290M
|
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
TPET | $0.4001 22.02% 35M
|
n/a
SRFM 4 | $0.6 21.29% 850K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.